Vedolizumab Edges Out Infliximab for Ulcerative Colitis in Real-World Study

(MedPage Today) -- ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor antagonist vedolizumab slightly...